{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:48:00Z","timestamp":1768517280070,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s13346-015-0254-y","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T16:11:12Z","timestamp":1440691872000},"page":"531-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Systems Approach to targeted and long-acting HIV\/AIDS therapy"],"prefix":"10.1007","volume":"5","author":[{"given":"Rodney J. Y.","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer P.","family":"Freeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefin","family":"Koehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"key":"254_CR1","doi-asserted-by":"crossref","unstructured":"Ho RJY, Gibaldi M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs. 2nd ed. Hoboken: Wiley-Blackwell; 2013.","DOI":"10.1002\/9781118660485"},{"key":"254_CR2","doi-asserted-by":"crossref","first-page":"D1118","DOI":"10.1093\/nar\/gkt1129","volume":"42","author":"C Qin","year":"2014","unstructured":"Qin C et al. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res. 2014;42:D1118\u20131123. doi: 10.1093\/nar\/gkt1129 .","journal-title":"Nucleic Acids Res"},{"key":"254_CR3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711\u20135. doi: 10.1038\/nrd1470 .","journal-title":"Nat Rev Drug Discov"},{"key":"254_CR4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ahj.2014.12.001","volume":"169","author":"J Butler","year":"2015","unstructured":"Butler J et al. Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. Am Heart J. 2015;169:305\u201314. doi: 10.1016\/j.ahj.2014.12.001 .","journal-title":"Am Heart J"},{"key":"254_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","volume":"16","author":"Z Liu","year":"1997","unstructured":"Liu Z et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83\u201392.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"254_CR6","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1126\/science.1699273","volume":"249","author":"H Mitsuya","year":"1990","unstructured":"Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science. 1990;249:1533\u201344.","journal-title":"Science"},{"key":"254_CR7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","volume":"20","author":"A Castagna","year":"2006","unstructured":"Castagna A et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795\u2013803. doi: 10.1097\/01.aids.0000218542.08845.b2 .","journal-title":"AIDS"},{"key":"254_CR8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023\u201335. doi: 10.1056\/NEJMra025195 .","journal-title":"N Engl J Med"},{"key":"254_CR9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","volume":"376","author":"JS Montaner","year":"2010","unstructured":"Montaner JS et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia Canada: a population-based study. Lancet. 2010;376:532\u20139. doi: 10.1016\/S0140-6736(10)60936-1 .","journal-title":"Lancet"},{"key":"254_CR10","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1097\/00002030-199905280-00001","volume":"13","author":"PR Harrigan","year":"1999","unstructured":"Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13:F59\u201362.","journal-title":"AIDS"},{"key":"254_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.qai.0000214822.33905.87","volume":"42","author":"L Kinman","year":"2006","unstructured":"Kinman L et al. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr. 2006;42:155\u201361. doi: 10.1097\/01.qai.0000214822.33905.87 .","journal-title":"J Acquir Immune Defic Syndr"},{"key":"254_CR12","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","volume":"111","author":"CV Fletcher","year":"2014","unstructured":"Fletcher CV et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014;111:2307\u201312. doi: 10.1073\/pnas.1318249111 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"254_CR13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1086\/315178","volume":"181","author":"T Schacker","year":"2000","unstructured":"Schacker T et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis. 2000;181:354\u20137. doi: 10.1086\/315178 .","journal-title":"J Infect Dis"},{"key":"254_CR14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","volume":"40","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159\u201368. doi: 10.2165\/00003088-200140030-00002 .","journal-title":"Clin Pharmacokinet"},{"key":"254_CR15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17460441.2.1.51","volume":"2","author":"GL Trainor","year":"2007","unstructured":"Trainor GL. The importance of plasma protein binding in drug discovery. Expert Opin Drug Discovery. 2007;2:51\u201364. doi: 10.1517\/17460441.2.1.51 .","journal-title":"Expert Opin Drug Discovery"},{"key":"254_CR16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jamainternmed.2013.6841","volume":"173","author":"HI Hall","year":"2013","unstructured":"Hall HI et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173:1337\u201344. doi: 10.1001\/jamainternmed.2013.6841 .","journal-title":"JAMA Intern Med"},{"key":"254_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00126334-200312010-00005","volume":"34","author":"L Kinman","year":"2003","unstructured":"Kinman L et al. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr. 2003;34:387\u201397.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"254_CR18","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1128\/AAC.02748-13","volume":"58","author":"J Koehn","year":"2014","unstructured":"Koehn J, Ho RJ. Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs lopinavir, ritonavir, and tenofovir in plasma. Antimicrob Agents Chemother. 2014;58:2675\u201380. doi: 10.1128\/AAC.02748-13 .","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"254_CR19","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/01.qai.0000137001.40505.56","volume":"37","author":"PJ Piliero","year":"2004","unstructured":"Piliero PJ. Pharmacokinetic properties of nucleoside\/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2004;37 Suppl 1:S2\u2013S12.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"254_CR20","author":"JP Freeling","year":"2014","unstructured":"Freeling JP, Koehn J, Shu C, Sun J, Ho RJ. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retrovir. 2014. doi: 10.1089\/aid.2014.0210 .","journal-title":"AIDS Res Hum Retrovir"},{"key":"254_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0005-2736(97)00122-3","volume":"1328","author":"C Oussoren","year":"1997","unstructured":"Oussoren C, Zuidema J. Crommelin, D. J. & Storm, G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta. 1997;1328:261\u201372.","journal-title":"Biochim Biophys Acta"},{"key":"254_CR22","volume-title":"Molecular biology of the cell","author":"B Alberts","year":"2002","unstructured":"Alberts B. Molecular biology of the cell. 4th ed. Science: Garland; 2002.","edition":"4"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-015-0254-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-015-0254-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-015-0254-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:55:15Z","timestamp":1559490915000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-015-0254-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1007\/s13346-015-0254-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]}}}